Kai Gu,Qi Li,Hongzhi Lin et al.
Kai Gu et al.
Gamma secretase (GS) is an intricate and multi-subunits complex, and it can cut various transmembrane proteins. Now it is a therapeutic target for a number of diseases. However, due to some side effects, the clinical development of GSI is n...
Novel fused pyrimidine and isoquinoline derivatives as potent HIV-1 NNRTIs: a patent evaluation of WO2016105532A1, WO2016105534A1 and WO2016105564A1 [0.03%]
新型 fused pyrimidine 和 isoquinoline 衍生物作为高效 HIV-1 非核苷类逆转录酶抑制剂：对专利 WO2016105532A1、WO2016105534A1 和 WO2016105564A1 的评价
Dongwei Kang,Zhipeng Huo,Gaochan Wu et al.
Dongwei Kang et al.
In the three patent applications, the impact of changing the pyrimidine core of the rilpivirine (RPV) to a variety of alternative fused cores was explored, culminating in the identification of a series of conformationally restricted compoun...
Carmela De Luca,Anastassia Trifonova
Carmela De Luca
Therapeutic antibodies have grown to become an important product class within the biopharmaceutical market. A prerequisite to their commercialization is adequate patent protection. Disclosure requirements and the types of claims available i...
Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II [0.03%]
神经生长因子受体酪氨酸激酶抑制剂的专利回顾（2010-2016）第二部分
Justin J Bailey,Ralf Schirrmacher,Kristen Farrell et al.
Justin J Bailey et al.
TrkA/B/C receptor activation supports growth, survival, and differentiation of discrete neuronal populations during development, adult life, and ageing but also plays numerous roles in human disease onset and progression. Trk-specific inhib...
Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I [0.03%]
神经生长因子受体酪氨酸激酶抑制剂的专利回顾（2010-2016）I部分
Justin J Bailey,Ralf Schirrmacher,Kristen Farrell et al.
Justin J Bailey et al.
Tropomyosin receptor kinases (TrkA/B/C) play crucial roles in the development and maintenance of the nervous system, and aberrant expression of Trk has been implicated in neurological disorders as well as neural and non-neural neoplasms. Pa...
Feng-Chi Chen
Feng-Chi Chen
Biotech patents are facing increasingly stern challenges. The patent statue holds that a multi-step method patent is not directly infringed unless all steps are carried out and attributed to a single entity. When separate steps are performe...
Progress of Middle East respiratory syndrome coronavirus vaccines: a patent review [0.03%]
中东呼吸综合征冠状病毒疫苗的研发进展：基于专利的回顾分析
Jiwon Choi,Mi-Gyeong Kim,Yu-Kyoung Oh et al.
Jiwon Choi et al.
Middle East respiratory syndrome coronavirus (MERS-CoV) has emerged as a new pathogen, causing severe complications and a high case fatality rate. No direct treatments are available as yet, highlighting the importance of prevention through ...
Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016) [0.03%]
富亮氨酸重复蛋白激酶2抑制剂专利回顾（2014-2016）
Paul Galatsis
Paul Galatsis
Leucine-rich repeat kinase 2 (LRRK2) is a member of the Tyrosine Kinase-Like (TKL) branch of the kinome tree and is a multi-domain protein that includes GTPase and kinase activity. While genome-wide association studies (GWAS) has linked LRR...
Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137) [0.03%]
新型组蛋白去乙酰酶6(HDAC6)选择性抑制剂：一项专利评估(WO2014181137)
Claudia A Simões-Pires,Philippe Bertrand,Muriel Cuendet
Claudia A Simões-Pires
Histone deacetylases (HDACs) are known to deacetylate histones and other proteins, which makes HDAC inhibitors able to affect cell survival, cell signaling, transport, and gene expression. Those effects have been associated to the therapeut...
Small-molecule HIV-1 entry inhibitors targeting gp120 and gp41: a patent review (2010-2015) [0.03%]
靶向gp120和gp41的HIV-1小分子侵入抑制剂专利回顾（2010-2015）
Wen Li,Lu Lu,Weihua Li et al.
Wen Li et al.
It is essential to discover and develop small-molecule HIV-1 entry inhibitors with suitable pharmaceutical properties. Areas covered: We review the development of small-molecule HIV-1 entry inhibitors as evidenced in patents, patent applica...